Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration

被引:46
|
作者
Leung, Ella H. [1 ,2 ]
Oh, Daniel J. [1 ]
Alderson, Shannon E. [1 ]
Bracy, Joshlynn [1 ]
McLeod, Mia [1 ]
Perez, Litzi, I [1 ]
Bottini, Alexander [1 ]
Yee, David Chin [1 ]
Mukkamala, Krishna [1 ]
机构
[1] Georgia Retina, Atlanta, GA USA
[2] 833 Campbell Hill St NW, Suite 300, Marietta, GA 30060 USA
来源
CLINICAL OPHTHALMOLOGY | 2023年 / 17卷
关键词
faricimab; intravitreal injection; neovascular age-related macular degeneration; intraocular inflammation; anti-vascular endothelial growth factor;
D O I
10.2147/OPTH.S409822
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the initial efficacy and safety of intravitreal faricimab in eyes previously treated for neovascular age-related macular degeneration (nARMD).Patients and methods: A retrospective review of all patients with nARMD previously treated with anti-vascular endothelial growth factor (anti-VEGF) injections who received at least 3 intravitreal faricimab injections with at least 3 months of follow-up.Results: A total of 190 eyes were included. Patients received a mean of 34.2 +/- 23 anti-VEGF injections over 182.41 +/- 128 weeks prior to switching to faricimab. Patients then received a mean of 6.99 +/- 2.3 faricimab injections with an average 34.88 +/- 8.2 weeks of follow-up. The mean best corrected visual acuities improved from 0.33 +/- 0.32 logMAR approximate to 20/43 to 0.27 +/- 0.32 logMAR approximate to 20/37 (P=0.0022). The central subfield thickness (CST) improved from 312 +/- 87 mu m to 287 +/- 71 mu m (P<0.0001). At the last clinical visit, 24% had no subretinal fluid or intraretinal fluid on optical coherence tomography. The mean dosing interval between the last two consecutive faricimab injections (7.64 +/- 6.2 weeks) was significantly longer than that for ranibizumab (5.16 +/- 2.0 weeks, P<0.001) or aflibercept (5.57 +/- 3.6 weeks, P<0.001). No patients developed idiopathic intraocular inflammation.Conclusion: Intravitreal faricimab was associated with improved vision and CSTs, even in treatment-resistant nARMD eyes. The mean last dosing interval for faricimab was longer than for ranibizumab or aflibercept. No significant adverse events were directly attributed to faricimab during the study.
引用
收藏
页码:1287 / 1293
页数:7
相关论文
共 50 条
  • [41] Faricimab in Treatment -Experienced Neovascular Age -Related Macular Degeneration
    Qaseem, Yaqoob
    Pettenkofer, Moritz
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [42] Consequences of Real-World Surveillance of Fellow Eyes in Neovascular Age-Related Macular Degeneration
    Onwuka, Oluchukwu
    Saddemi, Jackson L.
    Aydogmus, Fatma Sema Akkan
    Lasalle, Claudia C.
    Ramsey, David J.
    LIFE-BASEL, 2023, 13 (02):
  • [43] Exit Strategy for Treatment of Neovascular Age-Related Macular Degeneration in a Real-World Setting: Wishful Thinking?
    Eastline, Michael
    Said, Sadiq
    Bosch, Martina Monika
    Pascal, Knecht-Bosch
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2025,
  • [44] Consequences of Real-world Surveillance of Fellow Eyes in Neovascular Age-related Macular Degeneration
    Onwuka, Oluchukwu
    Saddemi, Jackson
    Akkan, F. Sema
    Lasalle, Claudia
    Ramsey, David J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [45] Experience With Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
    He, Lingmin
    Silva, Ruwan A.
    Ayoub, Noel
    Moshfeghi, Darius M.
    Leng, Theodore
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (05): : 542 - 549
  • [46] One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
    Rush, Ryan B.
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 2201 - 2208
  • [47] Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
    Kikuchi, Yusuke
    Kawczynski, Michael G.
    Anegondi, Neha
    Neubert, Ales
    Dai, Jian
    Ferrara, Daniela
    Quezada-Ruiz, Carlos
    OPHTHALMOLOGY SCIENCE, 2024, 4 (02):
  • [48] Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration
    Hang, Abraham
    Ngo, Taylor
    Virk, Jaipreet Singh
    Moussa, Kareem
    Moshiri, Ala
    Emami-Naeini, Parisa
    Park, Susanna S.
    CLINICAL OPHTHALMOLOGY, 2024, 18 : 3781 - 3789
  • [49] Visual and Anatomical Outcomes of Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration
    Gharbiya, Magda
    Iannetti, Ludovico
    Parisi, Francesco
    De Vico, Umberto
    Mungo, Maria Laura
    Marenco, Marco
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [50] Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME)
    Giancipoli, Ermete
    Guglielmi, Antonella
    Bux, Anna Valeria
    Clima, Giulia Maria Emilia
    Pignatelli, Francesco
    Boscia, Francesco
    Viggiano, Pasquale
    Boscia, Giacomo
    Fortunato, Francesca
    Besozzi, Gianluca
    Niro, Alfredo
    Dore, Stefano
    Iaculli, Cristiana
    OPHTHALMOLOGY AND THERAPY, 2024, 13 (08) : 2163 - 2184